NASDAQ · Biotechnology

Edesa Biotech, Inc. (EDSA) Stock

$3.51 -4.10% NASDAQ: EDSA Healthcare

Valuation

MetricValue
Price$3.51
Market Cap$33.81M
P/E Ratio-2.28
P/B Ratio3.95
P/S Ratio0.00
EPS (TTM)$-1.27
52-Week High$20.32
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-124.21%
ROA-110.85%
ROCE-166.02%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio12.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-24.0M$-18.0M$-9.0M$-7.0M$-8.0M
Net Profit$-13.0M$-18.0M$-8.0M$-6.0M$-7.0M
EPS$-7.73$-8.37$-2.93$-1.93$-1.27
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$15.0M$12.0M$9.0M$4.0M$14.0M
Total Liabilities$2.0M$2.0M$2.0M$2.0M$1.0M
Cash$8.0M$7.0M$5.0M$1.0M$11.0M
Borrowings$0$0$0$0$0

Latest News

EDSA: Positive Exploratory Data in Patients with AKI Zacks Small Cap Research · Jul 2, 2026 Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors GlobeNewswire · Jun 11, 2026 Sector Update: Healthcare Stocks Gain Friday Afternoon MT Newswires · Jun 5, 2026 Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board MT Newswires · Jun 5, 2026 Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients MT Newswires · Jun 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-12.0M$-7.0M$-5.0M$-7.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$-1.0M$-2.0M$-4.0M$10.0M
Free Cash Flow$-14.0M$-12.0M$-7.0M$-5.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.08
EV / EBITDA-1.88
FCF Yield-24.08%
Quick Ratio2.76
Interest Coverage0.00
Return 1Y207.11%
Return 3Y15.23%
Return 5Y-80.87%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRTXBioRestorative Therapies, Inc. $1.91 +1.06% -0.10 $2.64M 0.00%
COCPCocrystal Pharma, Inc. $1.07 +0.00% -1.49 $14.75M 0.00%
DWTXDogwood Therapeutics, Inc. $1.40 -0.71% -0.18 $47.08M 0.00%
ERNAErnexa Therapeutics Inc. $2.40 -3.61% -0.15 $3.92M 0.00%
EVGNEvogene Ltd. $0.38 -4.09% -0.44 $3.29M 0.00%

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is led by CEO Pardeep Nijhawan, employs 16 people, headquartered in CA, publicly traded since 2010.

Edesa Biotech, Inc. (EDSA) stock trades at $3.51 with a market capitalization of $33.81M. The stock is valued at a price-to-earnings (P/E) ratio of -2.28, price-to-book of 3.95, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.72 and $20.32, and currently trades 82.7% below its 52-week high.

On profitability, Edesa Biotech, Inc. generates a return on equity (ROE) of -124.21%, return on capital employed of -166.02%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides